Ascendis Pharma Files 6-K Report
Ticker: ASND · Form: 6-K · Filed: Nov 13, 2024 · CIK: 1612042
Sentiment: neutral
Topics: reporting, foreign-private-issuer
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a standard 6-K, nothing major to see here.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on November 13, 2024. This report is for the month of November 2024 and is filed by a foreign private issuer. The company is incorporated in G7 and its fiscal year ends on December 31.
Why It Matters
This filing indicates routine reporting for Ascendis Pharma A/S as a foreign private issuer, providing transparency to investors about its ongoing compliance and corporate status.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new material financial information or strategic changes.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 241453887 (company) — Film Number
- Tuborg Boulevard 12 (company) — Business Address
- DK-2900 Hellerup Denmark (company) — Business Address
FAQ
What type of filing is this?
This is a Form 6-K report of Foreign Private Issuer.
Who is the filer?
The filer is Ascendis Pharma A/S.
What is the SEC file number for Ascendis Pharma A/S?
The SEC file number is 001-36815.
When is the fiscal year end for Ascendis Pharma A/S?
The fiscal year end is December 31.
What is the primary business address of Ascendis Pharma A/S?
The primary business address is Tuborg Boulevard 12, DK-2900 Hellerup Denmark.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2024-11-13 16:02:00
Key Financial Figures
- $127.67 — y and has an exercise price equal to US $127.67 per share, the closing price of the Ame
Filing Documents
- d897455d6k.htm (6-K) — 13KB
- d897455dex11.htm (EX-1.1) — 1200KB
- g897455dsp174.jpg (GRAPHIC) — 3KB
- g897455dsp175.jpg (GRAPHIC) — 3KB
- g897455dsp177.jpg (GRAPHIC) — 3KB
- g897455dsp178.jpg (GRAPHIC) — 3KB
- g897455dsp179.jpg (GRAPHIC) — 3KB
- g897455dsp180.jpg (GRAPHIC) — 5KB
- g897455dsp_24a.jpg (GRAPHIC) — 4KB
- g897455dsp_25a.jpg (GRAPHIC) — 8KB
- g897455dsp_25b.jpg (GRAPHIC) — 3KB
- g897455dsp_26a.jpg (GRAPHIC) — 6KB
- g897455dsp_33a.jpg (GRAPHIC) — 4KB
- g897455dsp_33b.jpg (GRAPHIC) — 8KB
- g897455dsp_34a.jpg (GRAPHIC) — 3KB
- g897455dsp_34b.jpg (GRAPHIC) — 6KB
- g897455page43.jpg (GRAPHIC) — 4KB
- g897455page44a.jpg (GRAPHIC) — 8KB
- g897455page44b.jpg (GRAPHIC) — 3KB
- g897455page45.jpg (GRAPHIC) — 6KB
- 0001193125-24-257189.txt ( ) — 1334KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: November 13, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer